

DAFTAR PUSTAKA

- Abdi, F. (2015) 'Hepatitis B and pregnancy: An update review article', *World Journal of Obstetrics and Gynecology*, 4(1), p. 1. doi: 10.5317/wjog.v4.i1.1.
- Baergen, R. N. (2011) *Manual of Pathology of the Human Placenta*. doi: 10.1007/978-1-4419-7494-5.
- Balmasova, I. P. et al. (2014) 'Immunopathogenesis of chronic hepatitis B', *World Journal of Gastroenterology*, 20(39), pp. 14156–14171. doi: 10.3748/wjg.v20.i39.14156.
- Bhat, P. (2012) 'Maternal-Fetal Transmission of HBV', in *Maternal Fetal Transmission of Human viruses and their Influence in Tumorigenesis*, pp. 195–222.
- Blumenstein, M. et al. (2005) 'Suppressors of cytokine signaling proteins in human preterm placental tissues.', *Journal of molecular endocrinology*. England, 35(1), pp. 165–175. doi: 10.1677/jme.1.01767.
- Borgia, G. et al. (2012) 'Hepatitis B in pregnancy', *World Journal of Gastroenterology*, 18(34), pp. 4677–4683. doi: 10.3748/wjg.v18.i34.4677.
- Chang, M. H. (2007) 'Hepatitis B virus infection', *Seminars in Fetal and Neonatal Medicine*, 12(3), pp. 160–167. doi: 10.1016/j.siny.2007.01.013.
- Chen, P. et al. (2017) 'Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high

levels of HBV DNA: A community-based study', *Medicine (United States)*, 96(33), pp. 1–4. doi: 10.1097/MD.0000000000007766.

Faye, O. M. (2006) *Handbook of placental pathology*.

Fourati, S. and Pawlotsky, J.-M. (2016) 'Recent advances in understanding and diagnosing hepatitis B virus infection', *F1000Research*, 5(0), p. 2243. doi: 10.12688/f1000research.8983.1.

Gentile, I. and Borgia, G. (2014) 'Vertical transmission of hepatitis B virus: Challenges and solutions', *International Journal of Women's Health*, 6(1), pp. 605–611. doi: 10.2147/IJWH.S51138.

Hao HY et all. (2017) 'Relationship between HBeAg from HBsAg positive mothers and its influence on HBV intrauterine transmission', *PubMed*, 38(10), pp. 1410–1414.

Hospital, C. (2012) 'Laboratory User Handbook', 44(06), pp. 1–102.

Islam, M. et al. (1970) 'Clinical Significance Of Serum HbeAg Among HbsAg Positive Patients', *Faridpur Medical College Journal*, 5(2), pp. 50–52. doi: 10.3329/fmcj.v5i2.6821.

Kementerian Kesehatan (2014) 'InfoDATIN: Situasi dan Analisi Hepatitis', *Pusat Data dan Informasi*, p. 8. doi: 24427659.

Leong, J., Lin, D. and Nguyen, M. H. (2016) 'Hepatitis B surface antigen escape mutations: Indications for initiation of antiviral therapy revisited',

World Journal of Clinical Cases, 4(3), p. 71. doi: 10.12998/wjcc.v4.i3.71.

Li, Z., Hou, X. and Cao, G. (2015) 'Is mother-to-infant transmission the most important factor for persistent HBV infection?', *Emerging Microbes and Infections*, 4(5). doi: 10.1038/emi.2015.30.

Liu, J. et al. (2015) 'An "immune barrier" is formed in the placenta by hepatitis B immunoglobulin to protect the fetus from hepatitis B virus infection from the mother', *Human Vaccines and Immunotherapeutics*, 11(8), pp. 2068–2076. doi: 10.1080/21645515.2015.1010890.

Milich, D. R. (2016) 'The Concept of Immune Tolerance in Chronic Hepatitis B Virus Infection Is Alive and Well', *Gastroenterology*, 151(5), pp. 801–804. doi: 10.1053/j.gastro.2016.09.037.

Navabakhsh, B. et al. (2011) 'Hepatitis B Virus Infection during Pregnancy: Transmission and Prevention.', *Middle East journal of digestive diseases*, 3(2), pp. 92–102.

Nelson, N. P., Jamieson, D. J. and Murphy, T. V. (2014) 'Prevention of perinatal hepatitis B virus transmission', *Journal of the Pediatric Infectious Diseases Society*, 3(SUPPL1), pp. 7–12. doi: 10.1093/jpids/piu064.

Pereira, L. (2018) 'Congenital Viral Infection: Traversing the Uterine-Placental Interface', *Annual Review of Virology*, 5(1), p. annurev-virology-092917-043236. doi: 10.1146/annurev-virology-092917-043236.

Purdy M. A. (2017) 'Hepatitis B virus S gene escape mutants', *Asian*

journal of transfusion science, pp. 62–70. doi: 10.1186/s12879-017-2763-4.

Sarvel, D. et al. (2018) ‘Mother-To-child transmission of hepatitis B and C virus: Review of the epidemiology and current treatment options’, *Future Virology*, 13(1), pp. 43–52. doi: 10.2217/fvl-2017-0069.

Shrivastava, S. et al. (2013) ‘Increased regulatory T cells and impaired functions of circulating CD8 T lymphocytes is associated with viral persistence in Hepatitis B virus-positive newborns’, *Journal of Viral Hepatitis*, 20(8), pp. 582–591. doi: 10.1111/jvh.12078.

Tang, L. S. Y. et al. (2018) ‘Chronic Hepatitis B Infection’, *Jama*, 319(17), p. 1802. doi: 10.1001/jama.2018.3795.

Tran, T. T. (2011) ‘Immune tolerant hepatitis B: A clinical dilemma’, *Gastroenterology and Hepatology*, 7(8), pp. 511–516.

Trehanpati, N. et al. (2013) ‘Immunological mechanisms of hepatitis B virus persistence in newborns.’, *Indian Journal of Medical Research*, 138(5), pp. 700–710.

Voiculescu, M. (2015) ‘How far we are towards eradication of HBV infection’, *Journal of Gastrointestinal and Liver Diseases*, 24(4), pp. 473–479. doi: 10.15403/jgld.2014.1121.244.hbv.

Vyas, A. K. et al. (2017) ‘Immune balance in Hepatitis B Infection: Present and Future Therapies’, *Scandinavian Journal of Immunology*, 86(1), pp. 4–

14. doi: 10.1111/sji.12553.

Vyas, A. K. et al. (2018) 'Placental expression of asialoglycoprotein receptor associated with Hepatitis B virus transmission from mother to child', (April). doi: 10.1111/liv.13871.

Wang, F.-S. and Shi, J.-J. (2018) 'Immunopathogenesis of Hepatitis B Virus Infection', in *Hepatitis B Virus and Liver Disease*, pp. 45–62.

Yi, P. et al. (2016) 'Management of mother-to-child transmission of hepatitis B virus: Propositions and challenges', *Journal of Clinical Virology*. Elsevier B.V., 77, pp. 32–39. doi: 10.1016/j.jcv.2016.02.003.

Yu, Y. et al. (2017) 'Hepatitis B Virus e Antigen Activates the Suppressor of Cytokine Signaling 2 to Repress Interferon Action', *Scientific reports*. Nature Publishing Group UK, 7(1), p. 1729. doi: 10.1038/s41598-017-01773-6.

Lampiran 01

Etik Penelitian



	<p style="margin: 0; font-weight: bold;">KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN KOMITE ETIK PENELITIAN KESEHATAN RSPTN UNIVERSITAS HASANUDDIN RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR Sekretariat : Lantai 2 Gedung Laboratorium Terpadu JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245. Contact Person: dr. Agussalim Bukhari, M.Med.,PhD, Sp.GK TELP. 081241850858, 0411 5780103. Fax : 0411-581431</p>	
---	---	---

REKOMENDASI PERSETUJUAN ETIK

Nomor : 433/UN4.6.4.5.31/ PP36/ 2020


Tanggal: 13 Agustus 2020

dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20080377	No Sponsor	
Peneliti Utama	dr. Marlina	Sponsor	
Judul Peneliti	Ekspresi Supressor Of Cytokine Signaling-2 Pada Plasenta Ibu Hamil HBeAg Positif Dan HBeAg Negatif		
No Versi Protokol	1	Tanggal Versi	12 Agustus 2020
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Laboratorium Patologi Antomi Fakultas Kedokteran Universitas Hasanuddin Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 13 Agustus 2020 sampai 13 Agustus 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



Lampiran 02

Master Tabel

No	No Sample	Umur Ibu	Uta Getasai	BB Sbm Hamil	HBsAg	Anti HBC	Anti HBs	HBsAg e411	HBsAg	HBeAg	HBV DNA serum Ibu	HBV DNA Titer (Viralload)	DNA (PCR Nested) cord blood	SOCS2	HBV DNA PLASENTA	phase
1	003	27		1	1	0	0	569.5 IU/ml	0	0	194 IU/ml	0	0	+	3	
2	8	28	35	64	1	0	0	21.45 IU/ml	0	0	UNDETECTABLE	0	2	-	3	
3	14	29	39	55	1	1	0	2972 IU/ml	0	0	3798 IU/ml	0	0	-	3	
4	23	37	39		1	1	0	3542 IU/ml	0	0		0	3	+	3	
5	38	20	40	42	1	0	0	<0.05 IU/ml	0	0		0	1	-	3	
6	48	34	37	59	1	1	0	111.9 IU/ml	0	0		0	2	+	3	
7	79	20	38	38	1	1	0	45610 IU/ml	1	1		0	1	-	1	
8	94	36		60	1	1	1	137.5 IU/ml	0	0	8 IU/ml	0	0	-	3	
9	560	18	37		1	0	0	1.9444 IU/ml	0	1		0	1	-	4	
10	128	26	39		1	0	0	96360 IU/ml	1	1	1610730 IU/ml	0	3	+	1	
11	129	33	41	54	1	1	0	213.2 IU/ml	0	0	5 IU/ml	0	1	-	3	
12	137	25		55	1	1	0	21750 IU/ml	0	0		0	3	-	3	
13	144	26	42		1	1	0	32220 IU/ml	1	1	48199 IU/ml	0	0	-	1	
14	145	27	40		1	0	0	<0.05 IU/ml	0	0		0	1	-	3	
15	147	35		52	1	1	0	438.3 IU/ml	0	0	UNDETECTABLE	0	1	+	3	
16	170	39	40	64	1	0	0	<0.05 IU/ml	0	0	UNDETECTABLE	0	1	+	3	
17	172	37		55	1	0	0	1 IU/ml	0	0	84 IU/ml	0	1	+	3	
18	177	35	38	52	1	1	0	7620 IU/ml	0	0		0	0	-	3	
19	181	28	40	65	1	1	0	4502 IU/ml	0	0	40 IU/ml	0	1	-	3	
20	213	38		49	1	1	0	516 IU/ml	0	0	UNDETECTABLE	0	2	-	3	
21	235	29	43	48	1	0	1	<0.05 IU/ml	0	0	UNDETECTABLE	0	0	-	3	

44	421	25	37	51	1	1	0	1479 IU/ml	1	0	26301 IU/ml	0	1	+	2
45	422	19			1	0	0	<0.05 IU/ml	0	0	UNDETECTABLE	0	0	-	3
46	424	31	36	48	1	1	0	22910 IU/ml	1	0	44350112 IU/ml	0	1	+	2
47	434	29	38		1	1	0	12060 IU/ml	1	1	39858 IU/ml	0	1	+	1
48	437	31	40	55	1	1	0	0.459 IU/ml	1	0	471 IU/ml	1	1	+	2
49	458	37		58	1	1	0	490.4 IU/ml	0	0	UNDETECTABLE	0	0	+	3
50	480	29	39		1	1	0	45.35 IU/ml	0	0		0	1	-	3
51	501	31	41	75	1	1	0	7.43 IU/ml	0	0	UNDETECTABLE	0	0	-	3
52	485	29	38	63	1	0	1	<0.05 IU/ml	0	0	53 IU/ml	0	1	-	3
53	486	38	41	48	1	1	0	618.5 IU/ml	0	0		0	0	-	3
54	587	27		50	1	1	0	890.8 IU/ml	0	0	2213 IU/ml	0	3	-	3
55	609	25	39		1	1	0	12085 IU/ml	1	0	18658034 IU/ml	0	1	-	2
56	641	32	41		1	1	0	5048 IU/ml	0	0		0	1	-	3
57	668	27	40	60	1	1	0	3674 IU/ml	0	0		0	0	-	3
58	673	24	37	52	1	1	0	1005 IU/ml	1	1	116499294 IU/ml	0	0	-	1
59	674	26	41		1	1	0	6932 IU/ml	1	0	1671264 IU/ml	0	1	-	2
60	701	23	40		1	0	0	0.094 IU/ml	0	0		0	1	-	3
61	703	27	39	48	1	1	0	366.9 IU/ml	1	0	54163035 IU/ml	0	0	-	2
62	705	34	38	62	1	1	0	2613 IU/ml	0	0	UNDETECTABLE	0	1	-	3
63	718	37	43	60	1	1	0	122.8 IU/ml	1	0		0	0	-	2

64	758	32	38	70	1	1	0	178.2 IU/ml	0	0	1044 IU/ml	0	0	-	3
65	848	23			1	0	0	<0.05 IU/ml	0	0	UNDETECTABLE	0	3	-	3
65	853	23			1	1	0	1412 IU/ml	0	0	7 IU/ml	0	1	-	3

Frequencies

		Statistics			
		Ekspresi SOCS2	HbeAg	HBVDNA Ibu	HBVDNA CordBlood
N	Valid	66	66	66	66
	Missing	0	0	0	0

Frequency Table

Ekspresi SOCS2

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	ekspresi kuat	5	7.6	7.6	7.6
	ekspresi sedang	7	10.6	10.6	18.2
	ekspresi lemah	23	34.8	34.8	53.0
	tidak terekspresi	31	47.0	47.0	100.0
	Total	66	100.0	100.0	

HbeAg


		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	positif	16	24.2	24.2	24.2
	negatif	50	75.8	75.8	100.0
	Total	66	100.0	100.0	


HBVDNA Ibu


		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	positif	11	16.7	16.7	16.7
	negatif	55	83.3	83.3	100.0
	Total	66	100.0	100.0	


HBVDNA CordBlood

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	positif	4	6.1	6.1	6.1
	negatif	62	93.9	93.9	100.0
	Total	66	100.0	100.0	









HBVDNA Ibu * HBVDNA CordBlood Crosstabulation


		Count	HBVDNA CordBlood		Total
			positif	negatif	
HBVDNA Ibu	positif	Count	2	9	11
		% within HBVDNA Ibu	18.2%	81.8%	100.0%
	negatif	Count	2	53	55
		% within HBVDNA Ibu	3.6%	96.4%	100.0%
Total		Count	4	62	66
		% within HBVDNA Ibu	6.1%	93.9%	100.0%

Chi-Square Tests

	Value	df	Asymp. Sig. (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	3.406 ^a	1	.065		
Continuity Correction ^b	1.331	1	.249		
Likelihood Ratio	2.565	1	.109		
Fisher's Exact Test				.126	.126
Linear-by-Linear Association	3.355	1	.067		
N of Valid Cases	66				


a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .67.

b. Computed only for a 2x2 table.



Crosstabs


		Case Processing Summary					
		Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
Ekspresi SOCS2 * HBVDNA Ibu		66	100.0%	0	.0%	66	100.0%



Crosstabs

Case Processing Summary

	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
HbeAg * Ekspresi SOCS2	66	100.0%	0	.0%	66	100.0%



Lampiran 04
Dokumentasi Penelitian



